GLIOBLASTOMA MULTIFORME: UMA REVISÃO DO PAPEL DA SINALIZAÇÃO A3AR NA EVOLUÇÃO DO TUMOR
Resumo
O glioblastoma multiforme é um astrocitoma de grau IV (OMS), sendo considerado o mais comum e também o mais agressivo. Uma das alternativas de tratamento é a manipulação de receptores de adenosina como o A3AR, essa manipulação poderia aumentar o tempo de sobrevida desses pacientes. Portanto, o foco dessa revisão é reunir diversos estudos acerca da capacidade do receptor A3AR de regular a morte celular, proliferação, imunossupressão e angiogênese através de vias de sinalização em GBMs.
Palavras-chave
Texto completo:
PDF (Enlgish) (English)Referências
Fuller CE, Jones DTW, Kieran MW. New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. Am Soc Clin Oncol Educ B. 2017;37:753-763. doi:10.14694/edbk_175088
Agnihotri S, Burrell KE, Wolf A, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz). 2013;61(1):25-41. doi:10.1007/s00005-012-0203-0
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015;152:63-82. doi:10.1016/j.pharmthera.2015.05.005
Faria MHG, Patrocínio RMS V., Rabenhorst SHB. Astrocitomas: Uma Revisão Abrangente. Arq Bras Neurocir. 2006;25(1):23-33.
Holland EC. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci U S A. 2000;97(12):6242-6244. doi:10.1073/pnas.97.12.6242
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
Delgado-Martín B, Medina MÁ. Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. Adv Sci. 2020;7(9). doi:10.1002/advs.201902971
Quezada C, Peigñan L, Segura R, et al. Glioblastoma multiforme y estudio de la resistencia a la quimioterapia mediada por transportadores ABC. Rev Med Chil. 2011;139(4):415-424. doi:10.4067/S0034-98872011000400001
Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals. 2013;6(12):1475-1506. doi:10.3390/ph6121475
Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(21):8130.
Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell. 2010;1(7):638-655. doi:10.1007/s13238-010-0078-y
Chen J, Li Y, Yu T-S, et al. A restricted cell population propagates glioblastoma growth following chemotherapy. Nature. 2012;488(7412):522-526. doi:10.1038/nature11287.A
Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: An enigmatic player in cell biology. Pharmacol Ther. 2008;117(1):123-140. doi:10.1016/j.pharmthera.2007.09.002
Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility. Chem Rev. 2008;108(1):238-263. doi:10.1021/cr0682195
Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA. Adenosine Receptors in Cancer. Vol 193.; 2009. doi:10.1007/978-3-540-89615-9
Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6(1):1-9. doi:10.1186/s40425-018-0360-8
Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19(6):355-367. doi:10.1016/j.molmed.2013.03.005.CD39
Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Physiol Behav. 2017;176(12):139-148. doi:10.1016/j.physbeh.2017.03.040
Takahashi T, Otsuguro K, Ohta T, Ito S. Adenosine and inosine release during hypoxia in the isolated spinal cord of neonatal rats. Br J Pharmacol. 2010;161(8):1806-1816. doi:10.1111/j.1476-5381.2010.01002.x
Quezada C, Garrido W, Oyarzún C, et al. 5′-Ectonucleotidase Mediates Multiple-Drug Resistance in Glioblastoma Multiforme Cells. J Cell Physiol. 2013;228(3):602-608. doi:10.1002/jcp.24168
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - An update. Pharmacol Rev. 2011;63(1):1-34. doi:10.1124/pr.110.003285
Synnestvedt K, Furuta GT, Comerford KM, et al. By Hypoxia-Inducible Factor-1 Mediates Permeability Changes in Intestinal Epithelia. October. 2002;110(7):993-1002. doi:10.1172/JCI200215337.Introduction
Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta - Biomembr. 2011;1808(5):1400-1412. doi:10.1016/j.bbamem.2010.09.020
Gessi S, Sacchetto V, Fogli E, et al. Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol. 2010;79(10):1483-1495. doi:10.1016/j.bcp.2010.01.009
Torres Á, Erices JI, Sanchez F, et al. Extracellular adenosine promotes cell migration/invasion of Glioblastoma Stem-like Cells through A3 Adenosine Receptor activation under hypoxia. Cancer Lett. 2019;446(January):112-122. doi:10.1016/j.canlet.2019.01.004
Rocha R, Torres Á, Ojeda K, et al. The adenosine A3 receptor regulates differentiation of glioblastoma stem-like cells to endothelial cells under hypoxia. Int J Mol Sci. 2018;19(4):1-12. doi:10.3390/ijms19041228
Torres A, Vargas Y, Uribe D, et al. Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget. 2016;7(41):67373-67386. doi:10.18632/oncotarget.12033
Vincenzi F, Targa M, Corciulo C, et al. The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. PLoS One. 2012;7(6). doi:10.1371/journal.pone.0039317
Abbrachio MP, Brambilla R, Ceruti S, et al. G-Protein-Dependent Activation of Phospholipase C by Adenosine A3 Receptors in Rat Brain. Mol Pharmacol. Published online 1994:4002.
Linden J, Auchampach JA, Jin X, Figler RA. The Structure and Function of A1 and A2B Adenosine Receptors. Life Sci. 1998;62(8):0-5.
Schulte G, Fredholm BB. Human adenosine A1, A(2A), A(2B), and A3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol. 2000;58(3):477-482. doi:10.1124/mol.58.3.477
Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix and diseases of the CNS. Trends Neurosci. 1998;21(2):75-80. doi:10.1016/S0166-2236(97)01169-7
Swapna Asuthkar, Kiran Kumar Velpula, Chandramu Chetty BG, Rao and JS. Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis, Chemosensitivity and Radiosensitivity. Oncotarget. 2012;3(11):1439-1454.
Lakka SS, Jasti SL, Gondi C, et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene. 2002;21(36):5601-5608. doi:10.1038/sj.onc.1205646
Uribe D, Torres Á, Rocha JD, et al. Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling. Mol Aspects Med. 2017;55:140-151. doi:10.1016/j.mam.2017.01.009
Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610-622. doi:10.1038/nrn2175
Apontamentos
- Não há apontamentos.
Revista Brasileira de Neurologia e Psiquiatria. ISSN: 1414-0365